Format

Send to

Choose Destination
Biol Blood Marrow Transplant. 2014 Aug;20(8):1080-8. doi: 10.1016/j.bbmt.2014.02.018. Epub 2014 Feb 26.

Primary prophylaxis of invasive fungal diseases in allogeneic stem cell transplantation: revised recommendations from a consensus process by Gruppo Italiano Trapianto Midollo Osseo (GITMO).

Author information

1
Department of Hematology, Azienda Policlinico Umberto I, Sapienza University of Rome, Rome, Italy. Electronic address: girmenia@bce.uniroma1.it.
2
Center for Q1 the Study of Myelofibrosis, IRCCS Fondazione Policlinico S. Matteo, University of Pavia, Pavia, Italy.
3
GIMEMA Foundation, Rome, Italy.
4
Stem Cell Transplant Unit, Fondazione Policlinico Tor Vergata, Tor Vergata University, Rome, Italy.
5
Hematology and Bone Marrow Transplant Center, Ospedale Maggiore, Parma, Italy.
6
Division of Hematology II, IRCCS S. Martino University Hospital e IST, Genoa, Italy.
7
Institute of Hematology and Medical Oncology, L. e A Seragnoli, Policlinico S.Orsola Malpigli, Bologna, Italy.
8
Department of Hematology, A.O. di Careggi, University of Florence, Florence, Italy.
9
Department of Oncology and Hematology, A.O. Citta' della Salute e della Scienza di Torino, P.O. Molinette, Torino, Italy.
10
Division of Infectious Diseases and Bone Marrow Transplant Unit, Giannina Gaslini Institute, Genoa, Italy.
11
AOU Meyer Children Hospital Medical Direction, Florence, Italy.
12
Pediatric Onco-hematology Unit, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
13
Hematology and Bone Marrow Transplant Unit, San Raffaele Hospital, Milan, Italy.
14
Pediatrics and Pediatric Hematology Unit, Az. Osp. S.Camillo-Forlanini, Rome, Italy.
15
Onco-hematology Unit, Ospedale Pediatrico Bambino Gesù, Rome, Italy.
16
Department of Infectious Diseases, IRCCS S. Martino University Hospital e IST, Genoa, Italy.
17
Institute of Hematology, Policlinic A. Gemelli, Sacred Heath Catholic University, Rome, Italy.
18
Oncology, Hematology and Hematopoietic Stem Cell Transplant Program, U.O. Pediatrics-Prof. Pession, S. Orsola-Malpighi, University of Bologna, Bologna, Italy.
19
Division of Hematology, Azienda Ospedaliera Giovanni XXIII, Bergamo, Italy.

Abstract

This document updates and expands the recommendations on primary prophylaxis of invasive fungal diseases (IFD) in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients, published in 2009 by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). A consensus process was undertaken to describe and evaluate current information and practice regarding risk stratification and primary antifungal prophylaxis during the pre-engraftment and postengraftment phases after allo-HSCT. The revised recommendations were based on the evaluation of recent literature including a large, prospective, multicenter epidemiological study of allo-HSCT recipients conducted among the GITMO transplantation centers during the period of 2008 to 2010. It is intended as a guide for the identification of types and phases of transplantation at low, standard, and high risk for IFD, according to the underlying disease, transplantation, and post-transplantation factors. The risk stratification was the critical determinant of the primary antifungal approach for allo-HSCT recipients.

KEYWORDS:

Allogeneic hematopoietic stem cell transplantation (HSCT); Antifungal prophylaxis; Consensus; Fungal infections

PMID:
24582783
DOI:
10.1016/j.bbmt.2014.02.018
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center